The evolution of the COVID-19 pandemic in paediatric patients with sickle cell disease: From Alpha to Omicron.
Olufunke Y MartinStefanie MarguliesBarbara Speller-BrownSuvankar MajumdarDeepika S DarbariAndrew D CampbellPublished in: British journal of haematology (2023)
We compare the impact of SARS-CoV-2 variants on healthcare utilization and clinical presentation in paediatric patients with sickle cell disease (SCD). One hundred and ninety-one unique patients with SCD and positive SARS-CoV-2 polymerase chain reactions were identified between March 2020 and January 2022. Hospitalizations, which accounted for 42% (N = 81) of cases, were highest during the Delta dominant era (48%) and lowest during Omicron (36%) (p = 0.285). The most common SCD-related complication was vaso-occlusive pain (37%, N = 71), which accounted for 51% of all hospital admissions (N = 41), and acute chest was highest in the Alpha variant era (N = 15). Overall, COVID-19 remained mild in clinical severity within most paediatric SCD patients.
Keyphrases
- sars cov
- sickle cell disease
- end stage renal disease
- healthcare
- intensive care unit
- ejection fraction
- emergency department
- chronic kidney disease
- newly diagnosed
- coronavirus disease
- prognostic factors
- respiratory syndrome coronavirus
- liver failure
- gene expression
- spinal cord
- neuropathic pain
- drug induced
- dna methylation
- health insurance
- patient reported outcomes
- patient reported